Aspirin for primary prevention of cardiovascular disease in women

Area of Science:

• Cardiology
• Preventive Medicine
• Women's Health

Background:

• Cardiovascular disease (CVD) is a leading cause of mortality in the US, with stroke disproportionately affecting postmenopausal women.
• Sex-based disparities exist in CVD care, including under-treatment of women with aspirin for secondary prevention.
• The efficacy and safety of aspirin for primary CVD prevention in women remain less certain than in secondary prevention.

Purpose of the Study:

• To review the current evidence on aspirin for primary prevention of cardiovascular disease (CVD) specifically in women.
• To provide evidence-based recommendations for the use of aspirin in this population.

Main Methods:

• Systematic review of existing literature on aspirin's role in primary CVD prevention.
• Analysis of studies focusing on women, considering both benefits (e.g., reducing CVD events) and risks (e.g., bleeding complications).

Main Results:

• Aspirin shows clear benefits in secondary CVD prevention, but its net benefit in primary prevention for women is less established.
• The balance between aspirin's cardioprotective effects and bleeding risks varies and requires careful individual assessment in women.
• Evidence suggests potential benefits but highlights the need for personalized risk-benefit analysis.

Conclusions:

• The decision to use aspirin for primary CVD prevention in women should be individualized, weighing potential benefits against bleeding risks.
• Further research may be needed to clarify optimal aspirin use strategies for primary CVD prevention in diverse female populations.
• Healthcare providers should consider patient-specific factors when making recommendations regarding aspirin therapy for primary CVD prevention in women.